Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé foci, Mali

Basáñez, M-G and Walker, M and Nutman, T B and Colebunders, R and Diarra, D and Coulibaly, M E and Soumaoro, L and Diallo, A A and Dicko, I and Sangare, M B and Coulibaly, S Y and Doumbia, S S and Dembélé, M and Sow, M and Coulibaly, Y I and Dolo, H (2020) Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé foci, Mali. Clinical Infectious Diseases. ISSN 1058-4838

[img]
Preview
Text
12630_Serological Evaluation-of-Onchocerciasis-and-Lymphatic-Filariasis-Elimination-in-the-Bakoye-and-Faleme-foci-Mali_Accepted.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

In Mali, ivermectin-based onchocerciasis elimination from the Bakoye and Falémé foci, reported in 2009–2012, was a beacon leading to policy shifting from morbidity control to elimination of transmission (EOT). These foci are also endemic for lymphatic filariasis (LF). In 2007–2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24–25 years of treatment to evaluate if onchocerciasis EOT and LF elimination as a public health problem (EPHP) have been achieved.